Novartis: FDA approves biosimilar to AbbVie's Humira

(CercleFinance.com) - On Wednesday the US Food and Drug Administration approved Hyrimoz, a generic version of AbbVie's Humira, to treat rheumatoid arthritis, adult Crohn's disease and plaque psoriasis.


Novartis' unit Sandoz said that the FDA has also granted approval for the treatment of juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

The active ingredient in Hyrimoz is an inhibitor of tumor necrosis factor (TNF), a protein that is overproduced in certain auto-immune conditions.

A study confirmed the safety of Hyrimoz, demonstrating therapeutic equivalence in treated patients.

The Novartis share is currently up 0.2% in Zurich.

Copyright (c) 2018 CercleFinance.com. All rights reserved.